Drug combinations comprising KRAS G12C inhibitors and the FAK inhibitor IN10018 showed promising synergistic effects against diverse cancer cells and multiple cancer models, including NSCLC, CRC, and pancreatic cancer. The gene discussed is PTK2; the disease is non-small cell lung carcinoma.